Search Resources (English): Women and Health Protection (WHP)

Results 41 - 50 of 63


Full circle: drugs, the environment and our health
Looks at the environmental contamination of rivers and lakes by chemical products from a public health perspective. Argues that the most health-promoting, cost-effective strategy for everyone is prevention. (See Details)
Published: 2004
SSRI antidepressants: their place in women's lives
Explores SSRI use in women and its effects. Also looks at alternatives to SSRIs. (See Details)
Published: 2005
Strategies for public consultation and citizen access at the Therapeutic Product Programme, Health Protection Branch
Proposes recommendations in response to national public consultations held in 1998-99, to address proposed changes to federal health protection legislation. (See Details)
Published: 2000
Health concerns for Diane-35: drug advertised widely to teens and doctors in Canada despite health warnings
Discusses the health concerns for Diane-35, a combination product advertised as a birth control pill and acne medication. Looks at how this drug is advertised to both physicians and consumers. (See Details)
Published: 2004
Transparency and the drug approval process at Health Canada
Argues that the federal government is protecting drug companies instead of the public by keeping information about the drug approval process secret. Examines the impact of this on women's health. (See Details)
Published: 2005
The marketing of fear
Examines the tactics of pharmaceutical companies, especially direct-to-consumer advertising. (See Details)
Published: 2000
Evra and the environment
Explains, by using the Evra patch as an example, how the drug approval process does not take drug disposal into account. Lists ways to prevent unused or expired medications from entering the ecosystem. (See Details)
Published: 2004
Complaint letter to Minister Tony Clement regarding DTCA of celebrex

This letter raises concerns about the risks to public health of an advertisement for a prescription drug, Celebrex (celecoxib), that aired on Canadian television. The letter asks Minister Tony Clement to take immediate regulatory action to stop this advertising campaign and to impose sanctions on the sponsor, Pfizer, to prevent future violations.

 (See Details)
Published: March 14, 2006
Complaint letter to Health Canada: Pfizer "toe-tag" ad

This letter to Health Canada argues that the pharmaceutical manufacturer, Pfizer, has been running television ads with misleading information on cardiovascular risks and using Canadian's fear of death from heart disease in order to promote sales of its product.  It urges Health Canada to take regulatory action on this campaign.

 (See Details)
Published: January 2004
An open letter to WTO members

This letter outlines Women and Health Protection's objections to efforts by the United States and other countries to limit the scope of diseases covered under the Doha Declaration of November 2001.

 (See Details)
Published: 2002